Mers Cepi How is cepi responding to mers? with no vaccines against mers currently available, cepi’s aim is to advance mers vaccine candidates through phase 2 clinical trials and potentially develop a ready reserve of vaccines that could be used to control regional outbreaks. "we are thrilled to be working with the university of oxford and cepi on the development of this important vaccine candidate," said bill enright, barinthus bio's chief executive officer. "there is an active need for a mers vaccine for at risk populations and travellers in the middle east.
Mers Cepi A partnership between cepi, barinthus biotherapeutics and the university of oxford aims to fast track the development of a potential vaccine for the prevention of middle east respiratory syndrome (mers). Cepi supports five mers cov vaccine candidates, including the most advanced human vaccines in development. of the three currently active projects, two have completed phase i trials and are preparing for phase ii. In a significant leap forward for combating the deadly middle east respiratory syndrome (mers) coronavirus, the coalition for epidemic preparedness innovations (cepi) has announced a $2.6 million investment to propel uvax bio’s groundbreaking mers vaccine candidate into preclinical trials. Barinthus biotherapeutics, formerly known as vaccitech, is getting a shot in the arm thanks to $34.8 million in funding to develop a middle east respiratory syndrome (mers) vaccine.
Mers Cepi In a significant leap forward for combating the deadly middle east respiratory syndrome (mers) coronavirus, the coalition for epidemic preparedness innovations (cepi) has announced a $2.6 million investment to propel uvax bio’s groundbreaking mers vaccine candidate into preclinical trials. Barinthus biotherapeutics, formerly known as vaccitech, is getting a shot in the arm thanks to $34.8 million in funding to develop a middle east respiratory syndrome (mers) vaccine. Cepi’s mers programme seeks to advance candidate vaccines through phase 2 trials and develop an investigational ready reserve that could be used to control future regional outbreaks. cepi has made significant investments to advance vaccines against other coronaviruses. “coronaviruses are one of the most urgent infectious disease threats the world faces, so it’s vital that we get on with developing medical defences against this particularly deadly one – mers,” said dr richard hatchett, cepi’s ceo. "coronaviruses are one of the most urgent infectious disease threats the world faces, so it's vital that we get on with developing medical defences against this particularly deadly one — mers," said dr richard hatchett, cepi's chief executive officer. Since cepi's inception in 2017, we have moved quickly to develop vaccines against mers—and our other priority pathogens, nipah virus and lassa virus.
Comments are closed.